Nucynta

See also: Generic Nucynta ER

Nucynta is a brand name of tapentadol, approved by the FDA in the following formulation(s):

NUCYNTA (tapentadol hydrochloride - tablet; oral)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: November 20, 2008
  
  Strength(s): EQ 100MG BASE ^[RLD], EQ 50MG BASE, EQ 75MG BASE
  

Has a generic version of Nucynta been approved?

No. There is currently no therapeutically equivalent version of Nucynta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nucynta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
  Patent 6,071,970
  Issued: June 6, 2000
  Inventor(s): Mueller; Alan L. & Balandrin; Manuel F. & VanWagenen; Bradford C. & DelMar; Eric G. & Moe; Scott T. & Artman; Linda D. & Barmore; Robert M.
  Assignee(s): NPS Pharmaceuticals, Inc.
  Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
  
  Patent expiration dates:
  
  
  • June 6, 2017
    
    ✓ 
    Patent use: RELIEF OF MODERATE TO SEVERE ACUTE PAIN
  
  



• 
  Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
  Patent 7,994,364
  Issued: August 9, 2011
  Inventor(s): Fischer; Andreas & Buschmann; Helmut & Gruss; Michael & Lischke; Dagmar
  Assignee(s): Gruenenthal GmbH
  A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
  
  Patent expiration dates:
  
  
  • June 27, 2025
    
    ✓ 
    Patent use: RELIEF OF MODERATE TO SEVERE ACUTE PAIN
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
  Patent RE39593
  Issued: April 24, 2007
  Inventor(s): Buschmann; Helmut & Strassburger; Wolfgang & Friderichs; Elmar
  Assignee(s): Gruenenthal GmbH
  1-phenyl-3-dimethylaminopropane compounds corresponding to the formula I a method of preparing them, and the use of these substances as analgesic active ingredients in pharmaceutical compositions.
  
  Patent expiration dates:
  
  
  • August 5, 2022
    
    ✓ 
    Patent use: RELIEF OF MODERATE TO SEVERE ACUTE PAIN
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 20, 2013 - NEW CHEMICAL ENTITY
  
  

See also...

• Nucynta Consumer Information (Drugs.com)
• Nucynta Consumer Information (Wolters Kluwer)
• Nucynta Consumer Information (Cerner Multum)
• Nucynta Advanced Consumer Information (Micromedex)
• Nucynta AHFS DI Monographs (ASHP)
• Tapentadol Consumer Information (Drugs.com)
• Tapentadol Consumer Information (Wolters Kluwer)
• Tapentadol Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Tapentadol Consumer Information (Cerner Multum)
• Tapentadol Advanced Consumer Information (Micromedex)
• Tapentadol Hydrochloride AHFS DI Monographs (ASHP)